T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

Researchers found that immune T cells reside in healthy brains, signaling between the gut and brain, a previously unknown ...

Researchers from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen have succeeded in treating a patient with a ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after ...

Shares of Cullinan Therapeutics Inc. fell in after-hours trading despite the company announcing a licensing agreement with ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs ...